Navigation Links
Transgene's Therapeutic Vaccine TG4010 Shows Promising Preliminary Phase IIb Data in Advanced Non-Small Cell Lung Cancer
Date:1/10/2008

STRASBOURG, France, January 10 /PRNewswire-FirstCall/ -- Transgene (Euronext Paris: FR0005175080) announces promising preliminary data from the Phase IIb trial evaluating its therapeutic vaccine TG4010 (MVA-MUC1-IL2) as an adjunct to first line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).

This on-going trial is a randomized, open label and controlled study designed to assess the efficacy of TG4010 in combination with cisplatin and gemcitabine compared to the chemotherapy regimen alone. The trial completed the enrolment of 148 patients at the end of May 2007 and was conducted in 27 centres located in France, Poland, Germany, and Hungary. The patients had NSCLC expressing MUC1, either stage IIIB with effusion or stage IV, and had not received prior systemic treatment for their advanced disease. Half of the patients received the combination regimen (TG 4010 vaccine plus chemotherapy) and the other half of the patients received chemotherapy alone.

The trial confirmed the favourable safety profile of TG4010 when associated to chemotherapy: most adverse events observed so far were considered related to chemotherapy as well as to the underlying disease. Hematological toxicity was equivalent in both treatment groups. Most frequent adverse events related to TG4010 were injection site reactions and asthenia, which are classical vaccine associated reactions.

Based on the local evaluations performed at investigation centres, results so far are showing a positive trend in favour of the combination of TG4010 with the chemotherapy. These results nevertheless remain subject to a centralised review process that is presently on-going.

"We report today encouraging trends on the preliminary results of our Phase IIb trial with TG4010 in non-small cell lung cancer" said Philippe Archinard, Chief Executive Officer of Transgene. "We expect to present data during the second quarter of this year and final data by the fourth qua
'/>"/>

SOURCE Transgene S.A.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. MedImmune Broadens Focus of Venture Capital Fund to Include New Therapeutic Areas
2. Mersana Therapeutics Appoints C. Boyd Clarke Chairman of the Board of Directors
3. Nektar Therapeutics President and CEO Howard W. Robin to Present At JPMorgan 26th Annual Healthcare Conference
4. Cell Therapeutics, Inc. (CTI) Hosts Conference Call to Discuss Update on Zevalin(R) Acquisition, CMS Reimbursement, and PIX301 Timeline
5. MultiCell Technologies To Increase Focus on Therapeutic Candidates
6. Sirnaomics Received Multiple Government Fundings For Its Multi-Targeted siRNA Therapeutics Programs
7. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
8. Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs
9. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
10. House and Senate Pass Medicare Legislation to Freeze 2008 Reimbursement for Therapeutic Radiopharmaceuticals at 2007 Levels
11. Lonza Withdraws Majority of Claims in Patent Lawsuit Against Northwest Biotherapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... , ... September 03, 2015 , ... ... its non-invasive hydration monitoring wearable early 2016. , The device, called the ... using proprietary optical and electrical sensing technology. These sensors track trending interstitial fluid ...
(Date:9/3/2015)... ... 03, 2015 , ... If you plan to attend the 27th annual ... also want to sign up for the tour of Framingham State University's newest addition ... walk through of the (8) chemistry teaching labs that are exclusively utilizing (49) ...
(Date:9/2/2015)... , Sept. 2, 2015 Axovant Sciences Ltd. (NYSE: ... of dementia, today announced upcoming presentations at three investor conferences: ... the Baird 2015 Healthcare Conference in New York ... Thursday, September 10 at 2:00 PM at the BioCentury NewsMakers ... Millennium Broadway Hotel & Conference Center , Thursday, September ...
(Date:9/2/2015)... DUBLIN , Sept. 2, 2015 /PRNewswire/ ... has announced the addition of Jain PharmaBiotech,s ... Companies" to their offering. ... the pharmaceutical and biotechnology industries is anticipated. ... of drug development - from formulations for ...
Breaking Biology Technology:Technology Startup Halo Wearables to Unveil Non-Invasive Hydration Monitoring Device Early 2016 2Erlab Invites You to Tour the Largest Installation of Filtered Fume Hoods in the World 2Axovant Sciences To Present At Upcoming Investor Conferences 2Axovant Sciences To Present At Upcoming Investor Conferences 3Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 2Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 3
... BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) announced ... granted orphan drug designation for 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate, ... (LEMS). 3,4-DAP has previously received orphan drug designation ... Committee for Medicinal Products for Human Use of the ...
... , ... rapidly growing,orthobiologics company, was named Europe,s fastest growing,Biotech/Pharmaceutical/Medical Technology/Equipment company ... East and Africa). , This annual ... ApaTech has achieved a rate of 8,318% over this period. ...
... , , ... to market Oralair(R) in both adults and children,through a ... been marketed, was the reference Member state. , ... Belgium, Bulgaria, Cyprus, the,Czech Republic, Estonia, France, Germany, Greece, ...
Cached Biology Technology:FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 4ApaTech is Europe's Fastest Growing Lifescience Company 2ApaTech is Europe's Fastest Growing Lifescience Company 3ApaTech is Europe's Fastest Growing Lifescience Company 4STALLERGENES is Granted a Marketing Authorization for Oralair(R) in Europe 2STALLERGENES is Granted a Marketing Authorization for Oralair(R) in Europe 3
(Date:9/2/2015)... , Sept. 2, 2015 About hand ... for enterprises, banks, government organizations, telecommunication and hospitals as ... Keys, identity badges, and numeric keypads are used to ... structure of palm and fingers of an individual, width ... geometry scanners with infrared light and reflectors can be ...
(Date:9/2/2015)... Sept. 2, 2015 Security of data ... enterprises, banks, government organizations, telecommunications, hospitals, as well ... were previously being used to prevent unauthorised access. ... authentication, wherein individuals could gain access to secure ... such as hardware devices and numeric codes. However, ...
(Date:9/2/2015)... 2, 2015 Biometric ... in a system which uses identical human characteristic ... vein, DNA and finger print. Increasing number of ... such system which provides high level of security. ... and tokens are vulnerable to attacks. Furthermore, Biometric ...
Breaking Biology News(10 mins):Global Hand Geometry Biometrics Market 2015-2019 2Global Hand Geometry Biometrics Market 2015-2019 3Global Biometrics Spending Market in the Government Sector 2015-2019 2Global Biometrics Spending Market in the Government Sector 2015-2019 3Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 2Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 3Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 4
... introduced ,Delicious, a new muscadine grape cultivar. ,Delicious, ripens ... fruit features exceptional taste and texture with an edible ... the potential for wine production. The name ,Delicious, was ... sampled the fruit., According to Dr. Dennis J. Gray, ...
... placed increasing demands on available water resources. In 2007, ... where the population approached two million people. The dual ... features frequent severe drought conditions has created an urgent ... meet resident and visitor demand., Las Vegas operates on ...
... vital component of good health. Like plants that thrive in ... case for the production of vitamin D. In the past ... sun exposure. From fear of the potential dangers of UV ... work and recreational environments centered on virtual reality, we are ...
Cached Biology News:Keeping golf courses green when fresh water is limited 2Keeping golf courses green when fresh water is limited 3The sunlight solution for better health 2The sunlight solution for better health 3
... The Bio-Stack is compatible with ... systems. Speed, ease of use and ... routine microplate process. When used with ... reagent dispenser, the Bio-Stacks small footprint ...
... use of small interfering RNA (siRNA) molecules ... interference,(RNAi) pathway have generated tremendous interest in ... for experimental use can be,synthesized in vitro, ... into the target cells in vitro or ...
... S&S Custom Array Service enables scientists who have ... to have FAST Slides printed with proteins from ... Processing of the arrays is performed by the ... S&S to discuss your needs with an expert ...
... demands of the routine trace metal analytical ... robust and simple to use instrumentation. The ... most challenging sample matrices found in the ... the toughest analytical challenges found in the ...
Biology Products: